Pharma: Clinic Roundup

• Janssen Research & Development LLC, of Raritan, N.J., a unit of Johnson & Johnson, reported that canagliflozin substantially lowered blood glucose levels when used as add-on therapy in patients on insulin therapy for Type II diabetes and who are considered to be at greater risk for cardiovascular disease.